InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
September 17 2020 - 7:30AM
InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company
developing anti-inflammatory therapeutics by targeting the
complement system, today announced two management appointments.
Effective October 1, 2020, Thomas Taapken, Ph.D. will join InflaRx
as Chief Financial Officer. Jordan Zwick has been promoted to Chief
Strategy Officer, effective immediately.
Prof. Niels C. Riedemann, Chief Executive
Officer and Founder of InflaRx, said: “I am delighted to welcome
Thomas to InflaRx. He brings extensive senior management expertise
in the public biopharmaceutical sector, including at companies with
marketed products, and is an ideal fit as we advance our late-stage
clinical development programs. Thomas has proven great leadership
capabilities and is an excellent addition to our C-suite. I am also
very pleased that Jordan has agreed to take on the newly created
role of Chief Strategy Officer at the Company. Jordan has extensive
experience in the U.S. biotech and pharma industry and strategic
development and has a great network. He has been instrumental for
various important developments in the Company and will foster our
U.S. strategic footprint.”
Prof. Riedemann continued: “I would further like
to take this opportunity to thank our outgoing CFO, Arnd Christ,
for his contributions to InflaRx and the great team spirit and hard
work he has provided throughout his 5 years in the Company. We all
wish him the very best for his future endeavors.”
Thomas Taapken, Ph.D., said: “I am thrilled to
join InflaRx as Chief Financial Officer at a very exciting time as
the Company starts its first Phase III trial. InflaRx has made
breakthrough discoveries in the area of anti-C5a
therapeutics. Their work is significantly contributing to
finding cures for several chronic inflammatory diseases, as well as
life-threatening diseases such as COVID-19-induced pneumonia. I
believe that IFX-1 has great potential, and, based on the data
available, I am convinced we will be able to develop a drug for
patients with serious inflammatory diseases and high unmet medical
needs. I am truly impressed with the team and the great work they
are doing and look forward to helping to move InflaRx into the next
stage in its development.”
Thomas Taapken, Ph.D. has over 25 years of
experience in the life sciences sector at senior management and
board levels. Prior to joining InflaRx, he was Executive Chairman
at Imcyse SA in Belgium, where he now serves as Chairman of the
Board. He previously held executive management positions as Chief
Financial Officer and Chief Executive Officer at several publicly
listed and private companies, including Medigene AG, Epigenomics AG
and Biotie Therapies (sold to Acorda Therapeutics in 2016). In
addition to Imcyse, Thomas has also served on the board of private
and public companies such as Scibase AB and Immunic Inc. He has
successfully completed public and private financings, business and
M&A transactions and worked in venture capital in both Germany
and the U.S. He holds a Ph.D. in organic chemistry from the
Technical University of Berlin and studied economics and physics at
the University of Göttingen.
Jordan Zwick has served as head of business
development and corporate strategy. With today’s announcement, he
will assume additional direct leadership responsibilities in the
U.S. operations and finance organization. He has over a decade of
finance, marketing and corporate development experience. As part of
the healthcare marketing team at Medtronic, he launched a cardiac
remote monitoring device in the acute care setting. Jordan next
joined the business development team at Salix Pharmaceuticals,
working on a wide range of transactions, including the $14.5B
acquisition of Salix by Valeant Pharmaceuticals (now Bausch Health
Companies) in 2015. Post-acquisition, he became Head of Strategy
for the Salix business segment, where he played a key role in the
turnaround story of Bausch Health. Jordan holds an Honors B.A. and
an M.S. in economics from Florida Atlantic University and an MBA
from the University of San Francisco.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage
biopharmaceutical company focused on applying its proprietary
anti-C5a technology to discover and develop first-in-class, potent
and specific inhibitors of C5a. Complement C5a is a powerful
inflammatory mediator involved in the progression of a wide variety
of autoimmune and other inflammatory diseases. InflaRx was founded
in 2007, and the group has offices and subsidiaries in Jena and
Munich, Germany, as well as Ann Arbor, MI, USA. For further
information please visit www.inflarx.com.
Contacts:
InflaRx N.V.Jordan Zwick –
Chief Strategy OfficerEmail: jordan.zwick[at]inflarx.deTel: +1
917-338-6523
MC Services AGKatja Arnold,
Laurie Doyle, Andreas Jungfer Email: inflarx[at]mc-services.eu
Europe: +49 89-210 2280U.S.: +1-339-832-0752
FORWARD-LOOKING STATEMENTSThis press release
contains forward-looking statements. All statements other than
statements of historical fact are forward-looking statements, which
are often indicated by terms such as “may,” “will,” “should,”
“expect,” “plan,” “anticipate,” “could,” “intend,” “target,”
“project,” “believe,” “estimate,” “predict,” “potential” or
“continue” and similar expressions. Forward-looking statements
appear in a number of places throughout this release and may
include statements regarding our intentions, beliefs, projections,
outlook, analyses and current expectations concerning, among other
things, our ongoing and planned preclinical development and
clinical trials; the impact of the COVID-19 pandemic on the
Company; the timing and our ability to commence and conduct
clinical trials; potential results from current or potential future
collaborations; our ability to make regulatory filings, obtain
positive guidance from regulators, and obtain and maintain
regulatory approvals for our product candidates; our intellectual
property position; our ability to develop commercial functions;
expectations regarding clinical trial data; our results of
operations, cash needs, financial condition, liquidity, prospects,
future transactions, growth and strategies; the industry in which
we operate; the trends that may affect the industry or us and the
risks, uncertainties and other factors described under the heading
“Risk Factors” in InflaRx’s periodic filings with the Securities
and Exchange Commission. These statements speak only as of the date
of this press release and involve known and unknown risks,
uncertainties and other important factors that may cause our actual
results, performance or achievements to be materially different
from any future results, performance or achievements expressed or
implied by the forward-looking statements. Given these risks,
uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
InflaRx NV (NASDAQ:IFRX)
Historical Stock Chart
From Apr 2023 to Apr 2024